Profound Medical Corp. 8-K

What Happened
Profound Medical Corp. (PROF) filed a Form 8-K on January 15, 2026 (Item 7.01, Regulation FD disclosure) to announce that Mount Sinai Hospital treated its first prostate cancer patient using the Company’s TULSA-PRO® system. The Company furnished a press release announcing the milestone as Exhibit 99.1 to the filing.

Key Details

• Filing date: January 15, 2026 (Current Report on Form 8-K, Item 7.01).
• Event: Mount Sinai Hospital performed its first prostate cancer treatment with TULSA-PRO®.
• Disclosure: Press release is furnished as Exhibit 99.1 (dated January 15, 2026).
• Report signed by Rashed Dewan, Chief Financial Officer, on behalf of the Company.

Why It Matters
This 8-K documents a clinical milestone—TULSA-PRO’s first documented patient treatment at a major medical center (Mount Sinai). For investors, the filing is a concrete record of clinical adoption and outreach activity by Profound Medical; it provides verifiable company disclosure about progress in real-world use of its prostate cancer treatment system.